Global Peptic Ulcer Drugs Market to Grow at a CAGR of 2.8%, 2017-2021 with AstraZeneca, Daewoong Pharmaceuticals, Eisai & Takeda Pharmaceutical Dominating - Research and Markets

DUBLIN--(BUSINESS WIRE)--The "Global Peptic Ulcer Drugs Market 2017-2021" report has been added to Research and Markets' offering.

The global peptic ulcer drugs market to grow at a CAGR of 2.80% during the period 2017-2021.

The report, Global Peptic Ulcer Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

The latest trend gaining momentum in the market is Bismuth-based quadruple therapy. Bismuth-based quadruple therapy has emerged as an alternative therapy to address the demand for anti-resistant drugs for the treatment of peptic ulcer. The traditional treatment regimen for peptic ulcer involves the use of clarithromycin or levofloxacin-based triple therapy, which became resistant to H. pylori bacteria, thus leaving most individuals untreated. To offset the impact of antibiotic resistance, the modern therapeutic approach for the treatment of peptic ulcer is based on bismuth-based quadruple therapy, which involves the use of drugs, such as bismuth salt, tetracycline, and metronidazole, for which antibiotic resistance is rarely encountered.

According to the report, one of the major drivers for this market is economics of treating ulcer. The under use of antibiotic therapy for the treatment of peptic ulcer associated with H. pylori infection not only leads to unnecessary loss of productivity but also causes enormous economic loss to the individual. As per a CDC report, approximately 10%-15% of peptic ulcer adults living in the US are in poor health condition and unable to perform routine activities.

Key vendors

• AstraZeneca,
• Daewoong Pharmaceuticals,
• Eisai,
• Takeda Pharmaceutical
  

Other prominent vendors

• GlaxoSmithKline
• Pfizer
  

Key Topics Covered:

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction

PART 05: Peptic ulcers: Disease overview

PART 06: Key clinical trials

PART 07: Market landscape

PART 08: Market segmentation by drug class

PART 09: Geographical segmentation

PART 10: Decision framework

PART 11: Drivers and challenges

PART 12: Market trends

PART 13: Vendor landscape

PART 14: Key vendor analysis

For more information about this report visit https://www.researchandmarkets.com/research/j93psh/global_peptic